These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 578467)
1. Pharmacokinetics and bioavailability of diltiazem (CRD-401) in dog. Kohno K; Takeuchi Y; Etoh A; Noda K Arzneimittelforschung; 1977 Jul; 27(7):1424-8. PubMed ID: 578467 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic model of diltiazem. Kölle EU; Ochs HR; Vollmer KO Arzneimittelforschung; 1983; 33(7):972-7. PubMed ID: 6684932 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and metabolism of diltiazem in man. Rovei V; Gomeni R; Mitchard M; Larribaud J; Blatrix C; Thebault JJ; Morselli PL Acta Cardiol; 1980; 35(1):35-45. PubMed ID: 6967667 [TBL] [Abstract][Full Text] [Related]
4. Metabolic fate of diltiazem. Distribution, excretion and protein binding in rat and dog. Nakamura S; Suzuki T; Sugawara Y; Usuki S; Ito Y; Kume T; Yoshikawa M; Endo H; Ohashi M; Harigaya S Arzneimittelforschung; 1987 Nov; 37(11):1244-52. PubMed ID: 3440032 [TBL] [Abstract][Full Text] [Related]
5. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs]. Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and absolute bioavailability of diltiazem in humans. Ochs HR; Knüchel M Klin Wochenschr; 1984 Apr; 62(7):303-6. PubMed ID: 6727272 [TBL] [Abstract][Full Text] [Related]
7. Effects of diltiazem Hydrochloride (CRD-401) on renal hemodynamics of dogs. Ishikawa H; Matsushima M; Matsui H; Honjo A; Hayashi M; Shindo T; Morifuji T; Okaybayashi M Arzneimittelforschung; 1978; 28(3):402-6. PubMed ID: 580748 [TBL] [Abstract][Full Text] [Related]
8. Comparative bioavailability of two tablet preparations of diltiazem in healthy volunteers. De Bernardis E; Candido P; Lorefice R; Picari M; Rizza V Arzneimittelforschung; 1992 Jan; 42(1):25-7. PubMed ID: 1586376 [TBL] [Abstract][Full Text] [Related]
9. Effects of diltiazem hydrochloride (CRD-401) on hepatic, superior mesenteric and femoral hemodynamics. Ishikawa H; Matsushima A; Matsui H; Shindo T; Morifuji T; Okabayashi M Arzneimittelforschung; 1978; 28(3):400-2. PubMed ID: 580747 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel starch acetate-diltiazem controlled release tablets in healthy human volunteers. Korhonen O; Kanerva H; Vidgren M; Urtti A; Ketolainen J J Control Release; 2004 Mar; 95(3):515-20. PubMed ID: 15023462 [TBL] [Abstract][Full Text] [Related]
11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of oral morphine sulfate in dogs: a comparison of sustained release and conventional formulations. Dohoo SE; Tasker RA Can J Vet Res; 1997 Oct; 61(4):251-5. PubMed ID: 9342447 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of theophylline in beagle dogs and asthmatic patients after multiple oral doses of sustained-release theophylline tablet formulation. Nosaka H; Takagi K; Hasegawa T; Ogura Y; Mizukami Y; Satake T Int J Clin Pharmacol Ther Toxicol; 1986 Oct; 24(10):528-35. PubMed ID: 3781672 [TBL] [Abstract][Full Text] [Related]
14. Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs. Nakamura S; Ohashi M; Suzuki T; Sugawara Y; Usuki S; Takaiti O Arzneimittelforschung; 1989 Sep; 39(9):1100-8. PubMed ID: 2590259 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Löbenberg R; Kim JS; Amidon GL Eur J Pharm Biopharm; 2005 May; 60(1):17-23. PubMed ID: 15848051 [TBL] [Abstract][Full Text] [Related]
16. Development and pharmacokinetics of a new sustained-release formulation of diltiazem. Thiercelin JF; Necciari J; Caplain H; Cournot A; Combes M; Desmolin H; Flouvat B J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S31-7. PubMed ID: 1706011 [TBL] [Abstract][Full Text] [Related]
17. In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride. al-Suwayeh SA; el-Helw AR; al-Mesned AF; Bayomi MA; el-Gorashi AS Boll Chim Farm; 2003; 142(1):14-20. PubMed ID: 12680034 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of a controlled release amoxicillin formulation. Arancibia A; González G; Icarte A; Arancibia M; Arancibia P Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):97-100. PubMed ID: 3557736 [TBL] [Abstract][Full Text] [Related]
19. [Comparative bioavailability and pharmacokinetics of Dolotren retard and Dolotren]. Honorato J; Montes B; Suárez J; Lucero ML; Valiente R Rev Med Univ Navarra; 1992; 37(1):7-16. PubMed ID: 1626168 [TBL] [Abstract][Full Text] [Related]
20. In vivo performance of controlled release pellets of diltiazem HCl. Nisarur-ur-Rahman ; K H Y; Jia Woei W Pak J Pharm Sci; 2005 Apr; 18(2):44-8. PubMed ID: 16431398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]